World Aids Day
The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.
Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.
Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.
HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.
AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.
A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.
Without treatment, however, HIV progresses through three stages:
- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.
- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.
- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.
Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.
AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.
HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.
AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.
The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.
For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.
While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."
Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.
The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.
Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.
Credit: iStock
Waking up at night can make it difficult to fall back asleep, especially when the mind becomes alert and starts racing. Neuroscientist Andrew Huberman has suggested a simple eye-movement routine that he says may help people drift back to sleep. But does it actually work?
The routine is performed with the eyes closed:
Huberman suggests repeating the sequence two to three times.
His theory is that the movements may interact with brain circuits involved in tracking the body's position, including pathways involving the eyes, brainstem and cerebellum.
Also read: Struggling With Sleep? Neurologist Shares 3 Simple Tips For Better Sleep Health
Shelby Harris, a psychologist and board-certified sleep expert, says there are reasonable grounds to try it, Women's World magazine reported.
“I think it’s a very reasonable thing to try. It’s free, low effort, carries essentially no risk and has solid reasons it could help,” Harris was quoted as saying.
She notes that sleep tends to become more fragmented with age.
“Sleep naturally becomes more fragmented with age, with less time in deep sleep and more time in the lighter stages where it’s easy to wake up,” Harris said.
Hormonal changes with age can also contribute to more fragile sleep in women. But a plausible explanation does not mean the technique has been proven.
Michael Grandner, a clinical psychologist and sleep researcher at the University of Arizona, told Inc.com that eye movements, balance signals, the brainstem and cerebellum all contribute to how the brain tracks the body's position in space.
However, he said he is “not aware of studies that have directly tested that chain of events, or clinical trials showing that this particular eye-movement exercise reliably shortens sleep onset.”
Brant Hasler, co-director of the Behavioral Sleep Medicine Training Program at the University of Pittsburgh School of Medicine, added that the technique does not resemble a validated behavioral sleep intervention.
According to Grandner, the exercise may be better understood as a relaxation or focused-attention technique.
He said he would place it “closer to a relaxation, focused-attention, or mindfulness exercise than to an established treatment for insomnia.”
The repetitive movements could give the mind something neutral to focus on instead of worrying, planning for the next day or checking whether sleep has returned.
Further, Hasler said bedtime activities can be useful when they occupy the mind without becoming stimulating. The eye exercise could work in that way, he said, “regardless of any additional effects via proprioception.”
The slow breathing paired with the exercise may also help with relaxation.
Hasler said expectancy effects could explain some positive experiences with the technique. Grandner also cautioned against repeatedly checking whether the trick is working.
If the exercise becomes another task to perform perfectly, “it could become another form of sleep effort, which can actually perpetuate insomnia,” he said.
Credit: iStock
Rabies is most often associated with dog-mediated transmission in humans, but the virus can infect a wide range of mammals. In 2026, unusual cases involving farm goats, beavers and Cape fur seals raised fresh questions about how rabies moves between species.
Since July 2026, multiple US jurisdictions have reported human rabies exposures involving known rabies vectors or animals in which rabies is less commonly reported. The CDC issued a health advisory on September 10 “in response to recent reports of increases in human exposures to rabid or possibly rabid animals.”
The concern is not limited to North America. At least 176 people had been bitten by rabid Cape fur seals along South Africa’s coastline by the end of 2025, while researchers have warned that the disease could spread to other marine mammal species.
In North Carolina in 2026, a wild skunk entered a pen containing baby goats, some of which later tested positive for rabies. Of the 284 people evaluated by local health departments, post-exposure prophylaxis (PEP) was recommended for 213. In Maryland, a 13-year-old boy was attacked by a beaver while swimming at a state park and required surgery for his injuries.
These cases raise a bigger question: Are unusual infections simply spillover from established rabies hosts, or can the virus establish sustained transmission in a new species? To understand this better, HealthandMe spoke to two experts.
Also read: US CDC Warns Of Rising Human Rabies Exposure Risk: How To Stay Safe
Dr Anish T S, Professor at the School of Public Health, Kerala University of Health Sciences, told HealthandMe that rabies can infect mammals, but an infected animal is not necessarily a reservoir host.
Genetic sequencing can help establish where an unusual infection came from and whether the virus is changing.
“So one thing that we can do is genetic analysis. If we are able to pick up these animals infected by rabies, we find what kind of rabies virus it is and do maybe a sequencing of the genome of this virus.”
“These kinds of analysis could be done still, but it is a question that whether this particular virus is changing its host or the virus is accumulating some kind of genetic mutations so that it can get maybe involved with some other animals. It can choose some other animals also as their host. It is actually a very pertinent question.”
The Cape fur seal cases add another dimension to this question, with sustained rabies transmission reported within the marine mammal population.
Dr NK Ganguly, former Director General of the Indian Council of Medical Research (ICMR), told HealthandMe that rabies in goats is rare, while beaver exposures need particular caution.
“Beaver is one animal where we have to be very careful.”
Dr Anish said rabies can also present as paralytic or “dumb” rabies, which may not show classic signs and could lead people to handle or treat an infected animal without recognizing the risk.
Dr Ganguly stressed the need for prompt medical care after exposure.
“The rabies incubation period is around 10 days. So if somebody has been exposed, they should be immediately vaccinated. And if the exposure is with a bite or something at the upper limbs, then they need to be given an antiserum as well as vaccinated.”
“So depending on the exposure, you are given a vaccine which is available, and you are also given the cocktail of antibodies, the monoclonal antibodies, which act immediately.”
Dr Ganguly said rabies can also circulate in wild and feral animals, including foxes, while cats and other species can also be infected.
He said surveillance should extend beyond dogs to domestic animals that are in close contact with them and to wildlife where feasible.
“Surveillance should include domestic animals also which are in close contact with the dogs.”
“There should be surveillance. There should be sentinel surveillance. We should carry out, if it is affordable.”
He also pointed to dog vaccination and sterilization, as well as bait vaccination for wildlife and stray animals.
Dr Anish said unusual infections need investigation to determine whether they are isolated spillover events or linked to changes in the virus.
“The real issue is if the virus is changing much because of mutations. Because rabies virus is not that much notorious for mutations. That is why most of our vaccines are working.”
He said genetic studies could help answer whether existing vaccines and treatments would remain effective if significant mutations emerge.
“So the genetic studies of the virus may give us the answers to these questions.”
For India, the experts said the priority remains breaking established dog-mediated transmission chains before focusing on less common pathways.
“If you just look at the rabies situation in India, we are not even able to manage the pure dog-mediated rabies. That is, people are bitten by rabid dogs and people are getting infected, and we are not able to have maybe full coverage of vaccination, and all the other things are actually the biggest concern,” Dr Anish said.
Dr Ganguly added that surveillance should include domestic animals also which are in close contact with the dogs.
"But essentially, in the urban areas, the dog is the main animal, and we should—the Supreme Court has given now a lot of directions in this particular regard—that the dogs may be sterilized," the expert said.
The pet dogs need to be vaccinated and other stray dogs should be taken to facilities where they need to be sterilized and they need to be vaccinated, the experts said.
Credit: AI
The current treatment course for high cholesterol is taking a daily tablet or regular injections over a long period. But instead, could a single treatment change the way high cholesterol is treated?
This possibility is being explored after a small first-in-human trial conducted by Cleveland Clinic found that one infusion of an experimental CRISPR gene-editing therapy lowered LDL, also called bad cholesterol, by about half and that the effect was still present a year later.
The treatment, called CTX310, is still experimental. The study involved just 15 people, so the findings are premature, not evidence that CRISPR can replace statins or other cholesterol medications.
The Phase 1 trial included people with lipid disorders who had not responded adequately to existing medications.
Participants received a single infusion of CTX310, at different doses, and researchers followed them for 12 months.
At the highest dose, LDL cholesterol was reduced by 52.5% after one year, while triglycerides fell by 47.8%. The reductions seen earlier in the trial therefore persisted for at least 12 months.
Additionally, no serious adverse side effects related to the treatment were reported during the one-year follow-up. However, the researchers plan to continue monitoring participants for 15 years, as recommended for gene-editing therapies.
CTX310 operates differently compared to conventional cholesterol medicines. The treatment uses CRISPR-Cas9 gene editing to target ANGPTL3, a gene involved in regulating fats circulating in the blood.
The therapy delivers the gene-editing machinery to the liver, where it switches off ANGPTL3. Lower activity of this gene can reduce levels of LDL cholesterol and triglycerides.
The idea is that instead of using daily medicines to keep cholesterol in check, doctors could make a long-lasting genetic change.
Also read: Preeclampsia May End With Pregnancy. Your Heart Risk May Not
Statins remain a reliable treatment approach for lowering LDL cholesterol and reducing cardiovascular risk. CTX310 has only been tested in a very small Phase 1 trial. Also, the study was primarily designed to examine the safety and explore whether the gene-editing treatment could produce a meaningful effect.
The fact that LDL remained lower after one year is promising and encouraging, but researchers still need to determine whether the treatment can safely maintain its effects over many years and, crucially, whether it reduces heart attacks, strokes and other cardiovascular events.
There is also a fundamental difference between cholesterol tablets and permanently altering a person’s DNA.
High cholesterol is often a long-term condition. Depending on their risk, patients may need cholesterol-lowering treatment for many years.
If CRISPR becomes a reality, people may no longer have to stick to a chronic treatment strategy for managing cholesterol.
"Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive," said Cleveland Clinic cardiologist Luke Laffin, M.D., first author of the study. "It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients."
© $2026 Times Horizon Private Limited